The earnings call highlighted significant progress in the development and pre-launch activities for Anaphylm, indicating promising market expansion opportunities. However, financial challenges, including revenue decline and increased net loss, along with market access barriers, present notable concerns.

Company Guidance -

Q3 2025

During Aquestive Therapeutics' second quarter 2025 earnings call, the company provided guidance on several fronts. They are on track with their FDA review process for Anaphylm, their sublingual epinephrine film, with an action date set for January 31, 2026. Aquestive recently submitted a 120-day safety update to the FDA and expects clarity on whether an advisory committee meeting will occur after the FDA's mid-cycle review. The company is preparing for a potential launch, focusing on securing financing and increasing product awareness among physicians and payers. The rescue market for severe allergic reactions is projected to grow from approximately 5 million to 10 million prescriptions annually, potentially reaching over $2 billion in global market value. Aquestive's financial guidance for 2025 remains unchanged, with expected total revenues between $44 million and $50 million and a non-GAAP adjusted EBITDA loss of $47 million to $51 million. The company ended the quarter with $60 million in cash, sufficient for the initial launch of Anaphylm, but they are exploring additional funding options.

FDA Review and Launch Preparation for Anaphylm

The company is on track with the FDA review process for Anaphylm, including pre-commercial launch activities and securing launch financing. The FDA action date is set for January 31, 2026.

Market Opportunity for Anaphylm

The rescue market for severe allergic reactions is expected to grow significantly. Surveys indicate a potential market shift from injectable to non-injectable products, with a market size of up to $2 billion annually.

International Expansion Plans

Meetings with regulatory bodies in Canada and the EU are secured, with plans to complete these meetings by the end of the year and begin filing preparations.

Base Business Growth

The base business showed year-over-year growth in Q2 2025, driven by strong international product performance.

Cash Position and Financial Stability

Aquestive ended the last quarter with $60 million in cash, providing sufficient initial launch funding for Anaphylm.

Aquestive Therapeutics (AQST) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AQST Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 10, 2025	2025 (Q3)	-0.15 / -	-0.13	―	―	―
Aug 11, 2025	2025 (Q2)	-0.17 / -0.14	-0.03	-366.67% (-0.11)
May 12, 2025	2025 (Q1)	-0.17 / -0.24	-0.17	-41.18% (-0.07)
Mar 05, 2025	2024 (Q4)	-0.13 / -0.19	-0.12	-58.33% (-0.07)
Nov 04, 2024	2024 (Q3)	-0.12 / -0.13	-0.03	-333.33% (-0.10)
Aug 06, 2024	2024 (Q2)	-0.12 / -0.03	-0.1	70.00% (+0.07)
May 07, 2024	2024 (Q1)	-0.09 / -0.17	0.11	-254.55% (-0.28)
Mar 05, 2024	2023 (Q4)	-0.09 / -0.12	-0.23	47.83% (+0.11)
Nov 06, 2023	2023 (Q3)	-0.11 / -0.03	-0.23	86.96% (+0.20)
Aug 07, 2023	2023 (Q2)	-0.12 / -0.10	-0.36	72.22% (+0.26)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AQST Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 11, 2025	$3.86	$3.78	-2.07%
May 12, 2025	$2.85	$2.29	-19.65%
Mar 05, 2025	$2.79	$2.58	-7.53%
Nov 04, 2024	$5.15	$4.76	-7.57%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Aquestive Therapeutics, Inc. (AQST) report earnings?

Aquestive Therapeutics, Inc. (AQST) is schdueled to report earning on Nov 10, 2025, After Close (Confirmed).

What is Aquestive Therapeutics, Inc. (AQST) earnings time?

Aquestive Therapeutics, Inc. (AQST) earnings time is at Nov 10, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is AQST EPS forecast?

AQST EPS forecast for the fiscal quarter 2025 (Q3) is -0.15.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing